chufangao/CTO huggingface dataset:
Clinical trial NCT04529499: Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients
Official title: A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients
Sponsor: Dr. Reddy's Laboratories Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study met pre-defined criteria for futility at interim analysis
Enrollment: 353.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-22
Primary completion date: 2021-01-22
Completion date: 2021-01-27
Clinical trial NCT03818997: Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
Official title: DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer: a Multi-center Phase II Trial
Acronym: DYNAMIC
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Company decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-12-31
Primary completion date: 2021-04-30
Completion date: 2022-04-30
Clinical trial NCT04939428: Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19
Acronym: MOVe-AHEAD
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 2441.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-11
Primary completion date: 2022-11-16
Completion date: 2022-11-16
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05381363: Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children
Official title: Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children
Sponsor: Children's Hospital of Fudan University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-01
Primary completion date: 2023-01-01
Completion date: 2023-01-01
Plan to share individual participant data: NO
Clinical trial NCT03635996: Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
Official title: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)
Sponsor: Milestone Pharmaceuticals Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study was stopped by the Sponsor
Enrollment: 169.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-10
Primary completion date: 2020-11-13
Completion date: 2020-11-13
Baseline population: Safety population
Clinical trial NCT03976375: Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Official title: A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 422.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-06-26
Primary completion date: 2023-08-11
Completion date: 2024-08-22
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03289455: CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
Official title: A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity Of AUTO3, a CAR T Cell Treatment Targeting CD19 And CD22 in Paediatric And Young Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Acronym: AMELIA
Sponsor: Autolus Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-26
Primary completion date: 2020-05-18
Completion date: 2020-05-18
Baseline population: Patients infused with AUTO3
Limitations and caveats: Early completion of the study leading to small numbers of patients analyzed from the Phase I part of the study.
Clinical trial NCT03860077: Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco
Official title: Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco
Acronym: SIREN
Sponsor: Brown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 57.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-10
Primary completion date: 2022-03-23
Completion date: 2022-03-23
Baseline population: Characteristics of randomized participants
Limitations and caveats: The study enrollment was slowed due to programming of the smartphone app; we intended to make up enrollment numbers, however, the COVID-19 pandemic severely affected our ability to recruit. We lost several months of recruitment due to shutdowns, and post-COVID recruitment rates were much lower than pre-COVID; perhaps due to concerns about in-person sessions despite measures taken to reduce contact.
Plan to share individual participant data: UNDECIDED
IPD sharing description: The investigators involved in this project intend to share findings from its research through publications and presentations. After all data have been collected and the results of the study have been published, de-identified data will be made available to other qualified investigators upon request. Institutions and/or individuals wishing to access any resources or data must contact the Principal Investigators. Persons requesting data must do so in writing, identifying their affiliation and how and by whom the data will be used. The request will be evaluated by the PIs and Co-Investigators to ensure that it meets reasonable demands of scientific integrity.
Clinical trial NCT03074695: DPE Technique in Labor Epidural for Morbidly Obese Women
Official title: A Randomized Controlled Trial for Epidural Labor Analgesia: Comparison of Dural Puncture Epidural With Standard Labor Epidural Techniques
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 141.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-01
Primary completion date: 2020-11-06
Completion date: 2020-11-06
Plan to share individual participant data: NO
Clinical trial NCT03687632: ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
Official title: A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Sponsor: Noveome Biotherapeutics, formerly Stemnion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-10
Primary completion date: 2020-08-18
Completion date: 2020-08-25
Plan to share individual participant data: NO
Clinical trial NCT03178487: A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis
Acronym: SELECT-AXIS 1
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 187.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-24
Primary completion date: 2019-01-21
Completion date: 2022-02-17
Baseline population: The full analysis set (FAS) includes all randomized participants who received at least one dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT04361058: Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
Official title: Graft-Versus-Tumor Augmentation With Nivolumab for High-Risk Patients With MDS and AML After Allogeneic Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide
Sponsor: SCRI Development Innovations, LLC (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: The single site that was deemed appropriate for this study was unable to enroll patients. Closed due to slow accrual.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-13
Primary completion date: 2021-04-20
Completion date: 2021-04-20
Plan to share individual participant data: NO
Clinical trial NCT04355364: Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)
Official title: Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19
Acronym: COVIDORNASE
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: No signal of benefit of treatment.
Enrollment: 77.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-21
Primary completion date: 2021-12-20
Completion date: 2021-12-20
Plan to share individual participant data: NO
Clinical trial NCT04356937: Efficacy of Tocilizumab on Patients With COVID-19
Official title: Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 243.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-20
Primary completion date: 2020-07-13
Completion date: 2020-08-27
Baseline population: All randomized patients
Plan to share individual participant data: NO
IPD sharing description: Request for IPD can be submitted to PI for review
Clinical trial NCT05153174: Study of Sulphoraphane in Chronic Kidney Disease
Official title: Safety, Feasibility and Efficacy of Sulforaphane (Avmacol) in Chronic Kidney Disease
Sponsor: University of Rochester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-02
Primary completion date: 2023-05-25
Completion date: 2023-06-08
Limitations and caveats: At the time of review with the Data Safety Monitoring Committee, the study had consented 21 patients and enrolled 18 patients out of 24 targeted. 2 of the 21 patients were randomized to a 6-tablet Arm, which was removed in the final Protocol Amendment due to moderate side effects/adverse events. 1 patient withdrew before study procedures.
Plan to share individual participant data: YES
IPD sharing description: IPD will be shared after publication
IPD time frame: May 2024 data is available. End date to be determined.
IPD access criteria: clinicaltrials.gov
Clinical trial NCT02706626: Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Official title: Phase 2 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Criterium, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Did not meet enrollment objectives.
Enrollment: 32.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-09
Primary completion date: 2020-10-08
Completion date: 2021-04-01
Baseline population: Patients were enrolled and assigned to a cohort based on previous treatment. Cohort A enrolled patients with disease progression on a next generation ALK TKI regardless of the number of lines of therapy. Cohort B enrolled patients who had received first line alectinib. Cohort C enrolled patients with disease progression on standard dose brigatinib and who tolerated the therapy
Limitations and caveats: The study was terminated for slow accrual. The enrollment in the clinical trial did not reach the target number of subjects needed to achieve target power and was insufficient to produce statistically reliable results
Plan to share individual participant data: NO
Clinical trial NCT04072874: Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
Official title: Evaluation of the Safety and Clinical Activity of Curaleish Lotion and Cream in the Topical Treatment of Cutaneous Leishmaniasis in Colombia
Acronym: Curaleish
Sponsor: Universidad de Antioquia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Tthe study is in the approval phase by local regulatory authorities
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-31
Primary completion date: 2021-02-28
Completion date: 2022-07-31
Plan to share individual participant data: NO
Clinical trial NCT03366857: Effect of Supplemental Oxygen on Perioperative BNP Concentration in Cardiac Risk Patients
Official title: Effect of Supplemental Oxygen on Perioperative Brain Natriuretic Peptide Concentration in Cardiac Risk Patients - A Prospective Randomized Clinical Trial
Sponsor: Medical University of Vienna (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 260.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-01
Primary completion date: 2019-12-31
Completion date: 2020-05-30
Clinical trial NCT03345953: Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome
Official title: Randomized Double Blind Parallel Groups Sequential, Placebo Controlled, Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (RLS)
Acronym: P13-04
Sponsor: Bioprojet (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study facing recruitment difficulties related to stringent eligibility criteria
Enrollment: 29.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-06
Primary completion date: 2020-04-29
Completion date: 2020-04-29
Plan to share individual participant data: NO
Clinical trial NCT04138485: Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
Official title: A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults With Systemic Sclerosis
Sponsor: CSL Behring (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Due to business reasons, not safety issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-20
Primary completion date: 2020-09-16
Completion date: 2020-09-16
Plan to share individual participant data: YES
IPD sharing description: CSL will consider requests to share Individual Patient Data (IPD) from systemic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.~Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.~If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
IPD time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
IPD access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.~An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.~The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
Clinical trial NCT01239797: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Official title: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)
Acronym: ELOQUENT - 2
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 646.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-06-20
Primary completion date: 2014-09-02
Completion date: 2021-04-21
Baseline population: Randomized: all participants randomized to any treatment group
Clinical trial NCT03455517: Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia
Official title: Activity and Safety of Front-linevenetoclax and Rituximab Association (VeRiTAs) in Young and Fit Patients With Chronic Lymphocytic Leukemia (CLL) and Umutated IGVH and/or Disrupted TP53. A Phase 2 Multicenter Study
Acronym: VeRitAs
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 77.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-31
Primary completion date: 2021-09-05
Completion date: 2023-05-11
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04838847: A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
Official title: COVID-19 (CoviCompareCV): A Phase 3, Non-randomized, Open Label Clinical Trial to Evaluate the Immunogenicity and Safety of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Adults Aged 65 Years or Above Compared to Younger Adults Aged 18-45 Years
Sponsor: CureVac (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The study was withdrawn based on an assessment of immunogenicity in elderly adults.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-01
Primary completion date: 2022-01-31
Completion date: 2022-09-30
Clinical trial NCT04304716: Regional Anesthesia for Head and Neck Reconstruction
Official title: Regional Anesthesia for the Management of Perioperative Pain for Free Flap Reconstruction of the Head and Neck: A Randomized Prospective Trial
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Withdrawn from the IRB
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-03-31
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Clinical trial NCT03927274: Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
Official title: A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Funding unavailable
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-20
Primary completion date: 2023-05-24
Completion date: 2023-05-24
Clinical trial NCT05192265: Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine
Official title: Comparative Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine in The Treatment of Acute Uncomplicated Malaria Among Children In South-West Nigeria
Sponsor: University of Ibadan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 172.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-20
Primary completion date: 2020-12-23
Completion date: 2020-12-23
Plan to share individual participant data: NO
Clinical trial NCT03098680: A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems
Official title: A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems
Acronym: PRIME
Sponsor: Cambridge University Hospitals NHS Foundation Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Unable to recruit in time before end of PhD studentship
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-24
Primary completion date: 2020-02-29
Completion date: 2020-02-29
Plan to share individual participant data: NO
Clinical trial NCT04870164: Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
Official title: A Phase 1, First-time-in-human, Dose Ascending Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MP0420 (a Novel Drug Candidate With Potential for Treatment of COVID-19) in Healthy Volunteers
Sponsor: Molecular Partners AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to hypersensitivity observed in 3 subjects, although no stopping rules were met, the Sponsor decided to halt recruitment for further investigation. After analysis of PK, i.m. administration was not required, and recruitment stopped.
Enrollment: 53.0 (ACTUAL)
Number of arms: 14.0
Start date: 2020-11-18
Primary completion date: 2022-01-06
Completion date: 2022-01-06
Clinical trial NCT05039736: A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
Official title: A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: 0 participants accrued
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-02-24
Primary completion date: 2023-05-03
Completion date: 2023-05-03